Humana Medicare Advantage Plans Targeting Hemlibra, Herceptin Hylecta With Step Therapy
Executive Summary
Fail first requirements for 2020 also target drugs for myelodysplastic syndrome and chronic obstructive pulmonary disease, building on the step therapy program launched by Humana in 2019.
You may also be interested in...
Novartis Likes US ‘Buy And Bill’ Market For PCSK9 Drug, But Price Will Be Key
Inclisiran's price relative to existing PCSK9 drugs will be key determinant in payer acceptance. Novartis says pricing will be within cost effectiveness range estimated by ICER.
Humana Jumps In: Medicare Part B Step Therapy Program Includes Cancer Drugs
Biopharma manufacturers view implementation of management tool in Medicare Advantage plans with concern, urge US Centers for Medicare and Medicaid Services to withdraw permission for use of step therapy for Part B drugs.
Medicare Seeks Input On Dispute Resolution, Civil Penalties For Rx Pricing Program
Calculating a ‘fair price’ for new versions of already negotiated moiety is also one of several that CMS is requesting input on in its recently released initial guidance on the negotiation program.